## **Kluwer Patent Blog**

## CSL Behring v. Common Services Agency – insufficiency, European Patent Office (Appeals Court), 23 January 2009

Mark Einerhand · Friday, January 23rd, 2009

The degree of effectiveness of the invention (here: the removal of prion proteins) is an issue related to the technical problem solved by the invention. This is to be considered when assessing inventive step, and is thus not relevant for sufficiency of disclosure. As the invention is sufficiently disclosed in the specification, the fact that none of the examples illustrate the claimed invention has no negative impact on the sufficiency of disclosure since a worked example is not necessary for the skilled person to be able to carry out the invention.

The full summary of this case has been posted on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

## Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

1

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.** The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Friday, January 23rd, 2009 at 8:12 am and is filed under Biologics, Case Law, EPC, Sufficiency of disclosure

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.